-------- Original Message --------
This week's FiercePharma Manufacturing is brought to you by BioWorld Today.
|
 | Dear Colleague- Given the steep decline in third quarter biotech fundraising – down 48 percent from the same period last year – it's no surprise that companies are looking for alternatives. And at the recent Foley & Lardner Life Sciences conference in San Diego, a panel debated the merits of considering mergers and acquisitions as a financing strategy rather than an exit strategy. (from Bioworld Today - 11/03/11) Read this story and more in BioWorld Today, the world’s leading biotechnology news and information source for 20 years. Delivered to your desktop every single business day, Bioworld Today gives you all the news you need to know to make good business decisions in the day ahead, you’ll learn: - What your competitors are doing … so you can easily identify opportunities and threats.
- Where the smart money is going … where top investors are placing their bets and who is raising funds.
- The latest technological innovations and discoveries … to clinical study results across the industry.
- What the FDA and Congress are up to… so you can prepare for coming changes, and recent approvals.
Start your Risk-Free subscription today and save over 50%! Best Regards, Jennifer Boggs
Assistant Managing Editor, BioWorld Today | 
For questions or comments call Customer Service at 404-262-5547 | New! 
Learn More | | |
Want to reach 15,000+ FiercePharma Manufacturing subscribers with your own message?
Contact ryan@fiercemarkets.com or call 202-824-5089.
About this email: In order to receive FiercePharmaManufacturing for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FiercePharmaManufac turing.
Click here to unsubscribe.
FierceMarkets 1900 L St. NW Suite 400 Washington, DC 20036 |
No comments:
Post a Comment